Loading...
XKRX
009420
Market cap988mUSD
Apr 30, Last price  
27,750.00KRW
1D
-1.07%
Jan 2017
111.03%
Name

Hanall Biopharma Co Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
10.14
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.41%
Rev. gr., 5y
5.08%
Revenues
138.94b
+2.99%
82,485,563,00091,890,326,00098,682,408,000106,903,737,00087,701,600,68076,027,305,22074,228,313,77080,879,668,14080,022,559,94082,881,524,07084,230,756,08091,839,350,940108,452,042,40088,602,270,090101,594,443,690109,995,418,980134,909,837,620138,943,698,750
Net income
-1.80b
L
-1,029,708,0001,170,025,000581,952,000213,659,000-14,525,740,000-2,922,595,000-21,498,897,000-12,658,084,910-7,077,356,9502,026,026,4205,813,253,6603,300,102,19019,174,349,79019,764,498,9208,896,137,170251,473,6403,508,607,550-1,804,843,470
CFO
9.36b
-68.42%
271,722,000-3,278,652,0004,742,178,0001,418,781,0007,413,981,1002,197,165,680-7,780,098,850-3,518,357,340-454,023,7003,950,368,12042,138,652,270-2,994,392,10020,490,918,610929,290,570839,871,90025,204,350,56029,642,920,0509,360,058,090
Earnings
Jul 23, 2025

Profile

Hanall Biopharma Co.,Ltd, a pharmaceutical company, researches, develops, and sells pharmaceutical products in South Korea and internationally. The company offers specialty drugs and over-the-counter products for the treatment of gastric and duodenal ulcers, gastritis, cerebrovascular and peripheral blood vessel disorder, hypertension, atherosclerotic symptom, acute coronary syndrome, atherothrombosis and thromboembolism, diabetes, osteoporosis, chronic kidney failure, hypothyroidism, vitamin D-resistant rickets, osteomalacia, erectile dysfunction, prostatic hyperplasia, candidiasis, various fungal infections, prostate cancer, formal, constipation, thin stools, bloating, bowel abnormal fermentation, and hemorrhoids. The company was founded in 1973 and is based in Seoul, South Korea.
URL
http://www.hanall.co.kr/
IPO date
Dec 18, 1989
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
138,943,699
2.99%
134,909,838
22.65%
109,995,419
8.27%
Cost of revenue
115,581,841
109,503,518
87,758,515
Unusual Expense (Income)
NOPBT
23,361,858
25,406,319
22,236,904
NOPBT Margin
16.81%
18.83%
20.22%
Operating Taxes
1,621,647
(306,075)
1,677,956
Tax Rate
6.94%
7.55%
NOPAT
21,740,211
25,712,395
20,558,948
Net income
(1,804,843)
-151.44%
3,508,608
1,295.22%
251,474
-97.17%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,701,768
(9,945,160)
BB yield
-0.08%
1.10%
Debt
Debt current
748,153
700,220
559,343
Long-term debt
2,147,475
1,880,839
2,061,457
Deferred revenue
7,758,467
14,410,225
15,291,013
Other long-term liabilities
1,350,591
876,219
617,992
Net debt
(57,624,631)
(113,542,411)
(53,535,350)
Cash flow
Cash from operating activities
9,360,058
29,642,920
25,204,351
CAPEX
(1,641,630)
(2,412,125)
(7,676,957)
Cash from investing activities
(27,492,829)
(11,887,229)
(10,592,439)
Cash from financing activities
759,589
(813,508)
(10,644,037)
FCF
16,468,032
34,798,970
7,147,045
Balance
Cash
24,706,378
56,497,111
53,934,070
Long term investments
35,813,880
59,626,360
2,222,079
Excess cash
53,573,073
109,377,979
50,656,378
Stockholders' equity
52,615,300
84,663,642
73,666,770
Invested Capital
126,292,975
118,131,701
133,899,657
ROIC
17.79%
20.40%
14.78%
ROCE
13.06%
12.53%
12.05%
EV
Common stock shares outstanding
52,240
50,692
50,816
Price
38,650.00
-12.75%
44,300.00
148.88%
17,800.00
-15.44%
Market cap
2,019,084,155
-10.09%
2,245,655,777
148.27%
904,520,564
-16.08%
EV
1,961,459,524
2,132,390,102
850,985,214
EBITDA
26,482,375
28,653,264
25,289,557
EV/EBITDA
74.07
74.42
33.65
Interest
70,967
63,863
21,875
Interest/NOPBT
0.30%
0.25%
0.10%